SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (151)8/16/1999 6:58:00 PM
From: Pseudo Biologist  Read Replies (3) of 427
 
Wow, this is great stuff.

Let me take a "devil's advocate" one-liner short shot at your list just for fun:

<<Out of the latter if you picked a 15 stock portfolio of:

VRTX - PI does not sell much. Co is too academic
GELX - know nothing about this one
ALKS - overvalued?
CLTR - Rituxan will eat its lunch. Who needs a murine radiolabeled Ab if simple chimeric molecule works just as well?
NPSP - know nothing about this one either
AVIR - live virus too dangerous, will never be approved
ALGO - know nothing about this one
CELG - thalidomide will stay as small niche drug. Other stuff too early stage. Chiral ritalin not enough benefit (see SEPR)
ELN - accountants are crooks. AD's stuff too early stage. Got taken by Neurex's scam.
TKTX - overvalued and Amgen will crush them in court
GENZ - niche diseases, complicated share structure with all those tracking baby genzymes cover up for scam
SEPR - seldane/allegra case was one in a million; all other ICEs will not show enough of a benefit. FDA has tied their hands to push Xopenex; given that, how can they ever compete with generics? Repeat for every other drug in their pipeline.
INCY - no science, no leverage, generic stuff; make money soon or else. HGSI's and MLNM's business plans proven superior.

Pretty superficial but probably more substantial than recent stuff from TSC -g-

P(S)B

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext